Merieux Alliance, the Merieux
family holding company, announces today that it changes its name to take on
the historic name of Institut Merieux. At a press conference held in Paris,
Alain Merieux reviewed the important role played by industrial biology in the
face of major public health challenges including infectious diseases, cancer,
personalized medicine, theranostics and nutrition. Along with Alexandre
Merieux and the management teams, he outlined the many strengths that
Institut Merieux and its companies-bioMerieux, Transgene, ABL and Silliker-
will rely upon to meet these challenges in three strategic areas:
- in vitro diagnostics,
-
immunotherapy ,
- food safety and nutrition.
"Today we are returning to a name with historic value: the name Institut
Merieux, created in 1897 by Marcel Merieux. We are especially attached to the
symbol this name represents, but above all it is a flag for our commitment to
serving the medicine of tomorrow," said Alain Merieux. "Now more than ever,
we intend to serve public health globally. This flag stands for longstanding
values that are as relevant today as they were yesterday: the long-term
vision that is essential for our bio-industrial activities, a resolutely
global approach, and growth driven by scientific innovation, upholding the
family and Pasteurian tradition."
Institut Merieux plans to mobilize all the scientific, industrial and
financial resources necessary to carry out its missions to serve medicine and
public health worldwide. Following the sale last August of the ShanH holding,
which controlled the Indian vaccine company Shantha Biotechnics, the
Institute has concentrated on the development of three key areas of activity,
with an emphasis on scientific innovation and an international presence.
Institut Merieux, through its companies, pursues an original,
innovation-based strategy focusing on: